China SXT Pharmaceuticals (SXTC) Receivables - Net (2018 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Receivables - Net for 9 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.

• Quarterly Receivables - Net fell 15.12% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (down 15.12% YoY) and the FY2026 annual result came in at $2.9 million, down 15.12% from the prior year.
• Receivables - Net eased to $2.9 million in Q1 2026 per SXTC's latest filing, from $3.3 million in the prior quarter.
• Over the last five years, Receivables - Net for SXTC reached as high as $4.1 million in Q1 2022 and fell as low as $2.8 million in Q3 2023.
• A 5-year average of $3.3 million and a median of $3.3 million in 2025 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2023 — Receivables - Net tumbled 30.8% — and 2024, when it gained 24.38%.
• Year by year, Receivables - Net stood at $4.0 million in 2022, then sank by 30.8% to $2.8 million in 2023, then climbed by 24.38% to $3.4 million in 2024, then slipped by 2.83% to $3.3 million in 2025, then decreased by 14.21% to $2.9 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $2.9 million, $3.3 million, and $3.4 million for Q1 2026, Q3 2025, and Q1 2025 respectively.